secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001070081-25-000018
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics Q1 net income $866.6M on Novartis deal; guides FY revenue $650-800M
--------------------------------------------------------------------------------

- Net income $866.6M vs loss $91.6M YoY, driven by $986.2M upfront from Novartis PTC518 license deal.
- Total net product & royalty revenue $189.9M; DMD franchise (Translarna+Emflaza) $134M, down YoY.
- Cash, equivalents & marketable securities $2.027B as of March 31, 2025, up from $1.14B at Dec 31, 2024.
- Positive CHMP opinion for Sephience (sepiapterin) in PKU; NDA under FDA review with PDUFA July 29, 2025.
- PTC518 Phase 2 PIVOT-HD met primary endpoint of dose-dependent blood HTT lowering; plans to discuss accelerated approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/0001070081-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008125000018/tmb-20250506x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer